Literature DB >> 25051284

Persistent lymphopenia after diagnosis of sepsis predicts mortality.

Anne M Drewry1, Navdeep Samra, Lee P Skrupky, Brian M Fuller, Stephanie M Compton, Richard S Hotchkiss.   

Abstract

OBJECTIVE: The objective of this study was to determine whether persistent lymphopenia on the fourth day following the diagnosis of sepsis predicts mortality.
METHODS: This was a single-center, retrospective cohort study of 335 adult patients with bacteremia and sepsis admitted to a large university-affiliated tertiary care hospital between January 1, 2010, and July 31, 2012. All complete blood cell count profiles during the first 4 days following the diagnosis of sepsis were recorded. The primary outcome was 28-day mortality. Secondary outcomes included development of secondary infections, 1-year mortality, and hospital and intensive care unit lengths of stay.
RESULTS: Seventy-six patients (22.7%) died within 28 days. Lymphopenia was present in 28-day survivors (median, 0.7 × 10 cells/μL; interquartile range [IQR], 0.4-1.1 × 10 cells/μL) and nonsurvivors (median, 0.6 × 10 cells/μL; IQR, 0.4-1.1 × 10 cells/μL) at the onset of sepsis and was not significantly different between the groups (P = 0.35). By day 4, the median absolute lymphocyte count was significantly higher in survivors compared with nonsurvivors (1.1 × 10 cells/μL [IQR, 0.7-1.5 × 10 cells/μL] vs. 0.7 × 10 cells/μL [IQR, 0.5-1.0 × 10 cells/μL]; P < 0.0001). Using logistic regression to account for potentially confounding factors (including age, Acute Physiology and Chronic Health Evaluation II score, comorbidities, surgical procedure during the study period, and time until appropriate antibiotic administration), day 4 absolute lymphocyte count was found to be independently associated with 28-day survival (adjusted odds ratio, 0.68 [95% confidence interval, 0.51-0.91]) and 1-year survival (adjusted odds ratio, 0.74 [95% confidence interval, 0.59-0.93]). Severe persistent lymphopenia (defined as an absolute lymphocyte count of 0.6 × 10 cells/μL or less on the fourth day after sepsis diagnosis) was associated with increased development of secondary infections (P = 0.04).
CONCLUSIONS: Persistent lymphopenia on the fourth day following the diagnosis of sepsis predicts early and late mortality and may serve as a biomarker for sepsis-induced immunosuppression.

Entities:  

Mesh:

Year:  2014        PMID: 25051284      PMCID: PMC4362626          DOI: 10.1097/SHK.0000000000000234

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  43 in total

1.  Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis.

Authors:  Pavan Brahmamdam; Shigeaki Inoue; Jacqueline Unsinger; Katherine C Chang; Jonathan E McDunn; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2010-05-18       Impact factor: 4.962

2.  Early assessment of leukocyte alterations at diagnosis of septic shock.

Authors:  Fabienne Venet; Fanny Davin; Caroline Guignant; Audrey Larue; Marie-Angélique Cazalis; Romain Darbon; Caroline Allombert; Bruno Mougin; Christophe Malcus; Françoise Poitevin-Later; Alain Lepape; Guillaume Monneret
Journal:  Shock       Date:  2010-10       Impact factor: 3.454

3.  Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.

Authors:  W D Döcke; F Randow; U Syrbe; D Krausch; K Asadullah; P Reinke; H D Volk; W Kox
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

4.  IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.

Authors:  Jacqueline Unsinger; Margaret McGlynn; Kevin R Kasten; Andrew S Hoekzema; Eizo Watanabe; Jared T Muenzer; Jacquelyn S McDonough; Johannes Tschoep; Thomas A Ferguson; Jonathan E McDunn; Michel Morre; David A Hildeman; Charles C Caldwell; Richard S Hotchkiss
Journal:  J Immunol       Date:  2010-03-03       Impact factor: 5.422

5.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

Authors:  Christian Meisel; Joerg C Schefold; Rene Pschowski; Tycho Baumann; Katrin Hetzger; Jan Gregor; Steffen Weber-Carstens; Dietrich Hasper; Didier Keh; Heidrun Zuckermann; Petra Reinke; Hans-Dieter Volk
Journal:  Am J Respir Crit Care Med       Date:  2009-07-09       Impact factor: 21.405

6.  Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis.

Authors:  Christian Torgersen; Patrizia Moser; Günter Luckner; Viktoria Mayr; Stefan Jochberger; Walter R Hasibeder; Martin W Dünser
Journal:  Anesth Analg       Date:  2009-06       Impact factor: 5.108

7.  The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states.

Authors:  François Hein; Frédéric Massin; Aurélie Cravoisy-Popovic; Damien Barraud; Bruno Levy; Pierre-Edouard Bollaert; Sébastien Gibot
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

Review 8.  Regulatory T cell populations in sepsis and trauma.

Authors:  Fabienne Venet; Chun-Shiang Chung; Guillaume Monneret; Xin Huang; Brian Horner; Megan Garber; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2007-10-03       Impact factor: 4.962

9.  Downregulation of CD40 ligand response in monocytes from sepsis patients.

Authors:  Anna Sinistro; Cristiana Almerighi; Chiara Ciaprini; Silvia Natoli; Emanuele Sussarello; Sara Di Fino; Francesca Calò-Carducci; Giovanni Rocchi; Alberto Bergamini
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

10.  Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients.

Authors:  Jorge Monserrat; Raul de Pablo; Eduardo Reyes; David Díaz; Hugo Barcenilla; Manuel R Zapata; Antonio De la Hera; Alfredo Prieto; Melchor Alvarez-Mon
Journal:  Crit Care       Date:  2009-02-25       Impact factor: 9.097

View more
  129 in total

Review 1.  Balance Between the Proinflammatory and Anti-Inflammatory Immune Responses with Blood Transfusion in Sepsis.

Authors:  Teresa C Rice; Amanda M Pugh; Charles C Caldwell; Barbara St Pierre Schneider
Journal:  Crit Care Nurs Clin North Am       Date:  2017-06-23       Impact factor: 1.326

Review 2.  Immune therapy in sepsis: Are we ready to try again?

Authors:  Roger Davies; Kieran O'Dea; Anthony Gordon
Journal:  J Intensive Care Soc       Date:  2018-04-04

Review 3.  Therapeutic Potential of B-1a Cells in COVID-19.

Authors:  Monowar Aziz; Max Brenner; Ping Wang
Journal:  Shock       Date:  2020-11       Impact factor: 3.454

4.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

Review 5.  Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis.

Authors:  Manu Shankar-Hari; Nicholas Culshaw; Benjamin Post; Eduardo Tamayo; David Andaluz-Ojeda; Jesús F Bermejo-Martín; Sebastian Dietz; Karl Werdan; Richard Beale; Jo Spencer; Mervyn Singer
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

6.  Glucocorticoids regulate the proliferation of T cells via miRNA-155 in septic shock.

Authors:  Ying Chen; Guang Wang; Zhongmin Liu; Shiji Wang; Yushan Wang
Journal:  Exp Ther Med       Date:  2016-10-20       Impact factor: 2.447

7.  On the verge of using an immune toolbox in the intensive care unit?

Authors:  Frédéric Pène; Jean-Louis Vincent; Ignacio Martin-Loeches
Journal:  Intensive Care Med       Date:  2017-05-11       Impact factor: 17.440

8.  Sepsis: who will shoot first? Pharma or diagnostics?

Authors:  Julien Textoris; Anthony C Gordon
Journal:  Intensive Care Med       Date:  2018-06-14       Impact factor: 17.440

Review 9.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

10.  Gut Microbial Membership Modulates CD4 T Cell Reconstitution and Function after Sepsis.

Authors:  Javier Cabrera-Perez; Jeffrey C Babcock; Thamotharampillai Dileepan; Katherine A Murphy; Tamara A Kucaba; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.